Capitalization 7.76B 6.64B 6.19B 5.77B 10.62B 668B 11.84B 74.55B 28.26B 312B 29.11B 28.51B 1,145B P/E ratio 2025 *
35x
P/E ratio 2026 * 27.3x
Enterprise value 9.93B 8.5B 7.91B 7.38B 13.59B 854B 15.14B 95.38B 36.16B 400B 37.24B 36.48B 1,465B EV / Sales 2025 *
2.55x
EV / Sales 2026 * 2.4x
Free-Float
97.96%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Charles River Laboratories International, Inc.

1 day-0.85%
1 week+2.69%
Current month+4.16%
1 month+5.75%
3 months+48.26%
6 months-11.25%
Current year-14.39%
More quotes
1 week 155.48
Extreme 155.48
168.12
1 month 143.06
Extreme 143.06
168.12
Current year 91.86
Extreme 91.8609
193.56
1 year 91.86
Extreme 91.8609
254.15
3 years 91.86
Extreme 91.8609
275
5 years 91.86
Extreme 91.8609
460.21
10 years 59.99
Extreme 59.99
460.21
More quotes
Manager TitleAgeSince
Chief Executive Officer 74 1991-12-31
Director of Finance/CFO 52 2022-04-30
Chief Operating Officer 55 2021-11-10
Director TitleAgeSince
Chairman 74 1999-12-31
Director/Board Member 68 2017-07-04
Director/Board Member 70 2019-09-30
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.85%+2.69%-26.90%-24.90% 7.76B
+0.43%+1.98%+9.76%-0.39% 50.05B
+0.74%+4.63%+65.70%+43.32% 29.87B
-0.90%-1.01%+2.37%+6.36% 28.29B
-1.64%-1.43%-28.57%-24.47% 27.7B
+0.96%+1.78%+27.39%-22.98% 12.6B
-0.66%+1.31%-55.50%-27.05% 11.88B
-0.04%-0.62%+26.65%+104.38% 10.59B
+0.31%+1.58%+11.28%-1.04% 10.46B
+1.65%-0.33%+45.42% - 10.01B
Average +0.39%+0.90%+7.76%+5.91% 19.92B
Weighted average by Cap. +0.49%+0.98%+10.33%+5.64%
See all sector performances

Financials

2025 *2026 *
Net sales 3.9B 3.34B 3.11B 2.9B 5.34B 335B 5.94B 37.45B 14.2B 157B 14.62B 14.32B 575B 3.97B 3.4B 3.17B 2.95B 5.44B 342B 6.06B 38.16B 14.47B 160B 14.9B 14.59B 586B
Net income 222M 190M 177M 165M 303M 19.06B 338M 2.13B 807M 8.92B 831M 814M 32.7B 273M 233M 217M 203M 373M 23.46B 416M 2.62B 993M 10.98B 1.02B 1B 40.25B
Net Debt 2.17B 1.86B 1.73B 1.61B 2.97B 186B 3.31B 20.83B 7.9B 87.25B 8.13B 7.97B 320B 1.79B 1.53B 1.43B 1.33B 2.45B 154B 2.73B 17.21B 6.53B 72.11B 6.72B 6.58B 264B
More financial data * Estimated data
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (60.5%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (20.5%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (81.6%) and sales of products (18.4%). Net sales are distributed geographically as follows: the United States (55.3 Europe (26.6%), Canada (11.9%), Asia/Pacific (4.9%) and other (1.3%).
Employees
19,400
More about the company
Date Price Change Volume
25-07-14 158.04 $ -0.85% 646,945
25-07-11 159.40 $ -2.60% 518,978
25-07-10 163.66 $ +2.95% 828,706
25-07-09 158.97 $ +0.37% 653,998
25-07-08 158.39 $ +2.92% 752,391

Delayed Quote Nyse, July 14, 2025 at 04:00 pm EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
158.04USD
Average target price
159.67USD
Spread / Average Target
+1.03%
Consensus

Quarterly revenue - Rate of surprise